1 / 4

European Metabolic Disorder Therapeutics Market Size, Share, Analysis, Industry Report and Forecast - 2020-2026

<br>European metabolic disorder therapeutics market is estimated to grow at a CAGR of 7.4% during the forecast period. Rising prevalence of metabolic disorders have been reported in the region, which is accelerating the growth of the market. According to the International Diabetes Federation (IDF), an estimated 59 million adults (20-79 years) were suffering from diabetes in the Europe Region. Europe has the largest number of adolescents and children (0-19 years) have type 1 diabetes, which is 296,500. Diabetes is a form of metabolic diseases that disrupt normal metabolism. Diabetic medications that are used for the treatment of the condition include Metformin (Glucophage, Glumetza, others), Thiazolidinediones (rosiglitazone (Avandia) and pioglitazone (Actos)), and others.

pooja99
Télécharger la présentation

European Metabolic Disorder Therapeutics Market Size, Share, Analysis, Industry Report and Forecast - 2020-2026

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Orion Market Research European Metabolic Disorder Therapeutics Market Size, Share, Analysis, Industry Report and Forecast - 2020-2026 Request a free sample of our report on European Metabolic Disorder Therapeutics Market: https://www.omrglobal.com/request-sample/european-metabolic-disorder- therapeutics-market ------------------------------------------------------------------------------------------------------------------- Company Name: Orion Market Research Contact Person: Mr. Anurag Tiwari Email: info@omrglobal.com Contact no: +91 780-304-0404

  2. European metabolic disorder therapeutics market is estimated to grow at a CAGR of 7.4% during the forecast period. Rising prevalence of metabolic disorders have been reported in the region, which is accelerating the growth of the market. According to the International Diabetes Federation (IDF), an estimated 59 million adults (20-79 years) were suffering from diabetes in the Europe Region. Europe has the largest number of adolescents and children (0-19 years) have type 1 diabetes, which is 296,500. Diabetes is a form of metabolic diseases that disrupt normal metabolism. Diabetic medications that are used for the treatment of the condition include Metformin (Glucophage, Glumetza, others), Thiazolidinediones (rosiglitazone (Avandia) and pioglitazone (Actos)), and others. Rosiglitazone (Avandia) is intended for use as an adjunct to exercise and diet to improve glycemic control in adults suffering from type 2 diabetes mellitus. It is a highly potent and selective agonist for the peroxisome proliferator- activated receptor-gamma (PPAR?)-responsive genes that participate in the regulation of fatty acid metabolism. Request a free sample of our report on European Metabolic Disorder Therapeutics Market: https://www.omrglobal.com/request-sample/european-metabolic-disorder- therapeutics-market Based on country, the market is classified into UK, Germany, France, Spain, Italy, and Rest of Europe. UK is estimated to hold potential share in the market coupled with the significant prevalence of metabolic disorders in the country. As per the estimation by the Health Survey for England 2017, 28.7% of adults in England were obese and a further 35.6% are overweight. This leads to an increasing demand for metabolic drugs such as Orlistat (Xenical) and Phentermine. Orlistat (Xenical) works by reducing fat absorption by nearly 30%. A full report of European Metabolic Disorder Therapeutics Market is available at: https://www.omrglobal.com/industry-reports/european-metabolic-disorder-therapeutics- market European Metabolic Disorder Therapeutics Market Segmentation By Therapy •Drug Therapy •Gene Therapy •Cellular Transplantation

  3. •Enzyme Replacement Therapy •Others By Disease •Obesity •Diabetes •Lysosomal Storage Disease •Hypercholesterolemia •Others Regional Analysis •UK •Germany •France •Spain •Italy •Rest of European Company Profiles •AbbVie Inc. •Actelion Pharmaceuticals Ltd. •AstraZeneca plc •Boehringer Ingelheim GmbH •Bristol-Myers Squibb Co.

  4. •Merck KGaA •Novo Nordisk A/S •Orchard Therapeutics plc •Sanofi S.A. •Shire Pharmaceuticals Group plc For https://www.omrglobal.com/report-customization/european-metabolic-disorder- therapeutics-market more customized data, request for report customization @ About us: Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. For More Information, Visit https://www.omrglobal.com/ Media Contact: Company Name: Orion Market Research Contact Person: Mr. Anurag Tiwari Email: info@omrglobal.com Contact no: +91 780-304-0404

More Related